• Explore /
  • Poster
  • / Pilot trial of an indoleamine 2,3-dioxygenase-1 (IDO1) inhibitor plus a multipeptide melanoma vaccine in patients with advanced melanoma.

Pilot trial of an indoleamine 2,3-dioxygenase-1 (IDO1) inhibitor plus a multipeptide melanoma vaccine in patients with advanced melanoma.

Abstract Poster

Authors

Craig Slingluff

Craig L. Slingluff Jr.

University of Virginia School of Medicine, Charlottesville, VA

Craig L. Slingluff Jr., Steven Fling , Ileana S Mauldin , Marc S. Ernstoff , Brent Allen Hanks , Keith A. Delman , David H. Lawson , Brian Gastman , Judith C Kaiser , Martin A. Cheever

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2018 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Developmental Therapeutics—Immunotherapy

Track

Developmental Therapeutics and Translational Research

Sub Track

Biomarkers and Correlative Studies from Immunotherapy Trials

Clinical Trial Registration Number

NCT01961115

Citation

J Clin Oncol 36, 2018 (suppl; abstr 3033)

DOI

10.1200/JCO.2018.36.15_suppl.3033

Abstract #

3033

Poster Bd #

247

Abstract Disclosures

Similar Posters

First Author: Sofie Kirial Mørk

First Author: Mark Yarchoan

First Author: Oliver Klein

Poster

2013 ASCO Annual Meeting

Phase I study of peptide vaccine targeting indeolamine 2,3 dioxygenase in metastatic lung cancer patients.

Phase I study of peptide vaccine targeting indeolamine 2,3 dioxygenase in metastatic lung cancer patients.

First Author: Trine Zeeberg Iversen